HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

6-hydroxychlorzoxazone

chlorzoxazone metabolite in humans

Networked: 5 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzoxazoles: 68
      - Chlorzoxazone: 91
        6-hydroxychlorzoxazone: 5

Experts

1.	Lee, Inchul: 2 articles (07/2008 - 06/2003)
2.	Mehvar, Reza: 1 article (12/2011)
3.	Shaik, Imam H: 1 article (12/2011)
4.	Ahn, Choong Y: 1 article (07/2008)
5.	Bae, Soo K: 1 article (07/2008)
6.	Jung, Young S: 1 article (07/2008)
7.	Kim, Young C: 1 article (07/2008)
8.	Lee, Myung G: 1 article (07/2008)
9.	Shin, Wan G: 1 article (07/2008)
10.	Bies, Robert R: 1 article (12/2003)

Related Diseases

1.	Obesity 10/01/1994 - "Estimation of the fractional clearance of 6-hydroxychlorzoxazone showed that obesity increased this parameter to a similar extent as oral clearance. "
2.	Acute Kidney Injury (Acute Renal Failure) 06/01/2003 - "The purpose of this study is to report the changes of CYP2E1, CYP1A2, CYP2B1/2, CYP2C11, CYP3A23, and CYP3A2 expression and pharmacokinetics and tissue distribution of chlorzoxazone (CZX) and 6-hydroxychlorzoxazone (OH-CZX) in rats with acute renal failure induced by uranyl nitrate (U-ARF), and the role of CYP3A23 and CYP3A2 in the formation of OH-CZX in rats with U-ARF. "
3.	Kidney Diseases (Kidney Disease) 12/01/2003 - "The purposes of this study were (1) to describe the disposition of chlorzoxazone and 6-hydroxychlorzoxazone in patients with kidney disease, (2) to develop a population pharmacokinetic model including covariates that may influence the pharmacokinetic variability of both compounds, and (3) to examine the effect of covariates on the chlorzoxazone metabolic ratio. " 12/01/2003 - "The 6-hydroxychlorzoxazone area under the plasma concentration-time curve was inversely related to CL(cr), even within the range of normal renal function, resulting in chlorzoxazone metabolic ratio values that were substantially higher in subjects with kidney disease. " 12/01/2003 - "Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies." 12/01/2003 - "Although cytochrome P450 (CYP) 2E1 activity, as estimated by 6-hydroxychlorzoxazone formation clearance, was not affected by kidney disease, the chlorzoxazone metabolic ratio was substantially elevated in these subjects. "
4.	Ischemia 12/01/2011 - "Here, we investigated the effects of 1 h of partial ischemia, followed by 3 (IR3) or 24 (IR24) h of in vivo reperfusion, on the in vivo, isolated perfused rat liver (IPRL), and microsomal disposition of chlorzoxazone (CZX) and its cytochrome P450 2E1 (CYP2E1)-mediated metabolite, 6-hydroxychlorzoxazone (HCZX), in rats. "
5.	Diabetes Mellitus 07/01/2008 - "Pharmacokinetic parameters of chlorzoxazone and its main metabolite, 6-hydroxychlorzoxazone, after intravenous and oral administration of chlorzoxazone to liver cirrhotic rats with diabetes mellitus."

Related Drugs and Biologics

1.	Chlorzoxazone
2.	Cytochrome P-450 CYP2E1 (CYP2E1)
3.	Cytochrome P-450 CYP1A2 (CYP1A2)
4.	Cytochrome P-450 CYP2B1 (PROD)
5.	Uranyl Nitrate
6.	rat Cyp3a23-3a1 protein
7.	hydroxide ion
8.	Cytochrome P-450 Enzyme System (Cytochrome P450)

Related Therapies and Procedures

1.	Oral Administration